Details of the Drug Combination

General Information of Drug Combination (ID: DC72V60)

Drug Combination Name
NABILONE Ribavirin-TP
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs NABILONE   DMVRYT2 Ribavirin-TP   DM09NGV
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 48.63
Bliss Independence Score: 48.63
Loewe Additivity Score: 57.81
LHighest Single Agent (HSA) Score: 57.81

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of NABILONE
Disease Entry ICD 11 Status REF
Insomnia 7A00-7A0Z Approved [2]
NABILONE Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Cannabinoid receptor 2 (CB2) TTMSFAW CNR2_HUMAN Inhibitor [4]
Cannabinoid receptor 1 (CB1) TT6OEDT CNR1_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Indication(s) of Ribavirin-TP
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [3]
Ribavirin-TP Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Hepatitis C virus NS3 helicase (HCV NS3) TTWXB3E POLG_HCV1 Inhibitor [3]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 ATP-binding domain of NTPase/helicase as a target for hepatitis C antiviral therapy. Acta Biochim Pol. 2000;47(1):173-80.
4 Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.